In an article entitled, “Quick Takes on Promising New Approaches to Treating Breast Cancer”, the ASCO Post describes OBI-822/821 (OPT-822/OPT-821) as a “Vaccine Encouraging in Immune Responders”.

In addition to reviewing the results of the study that was unblinded last February 2016, the article quotes Steven J. Isakoff, MD, PhD, of Massachusetts General Hospital, Boston, who noted: “The primary synthroidnews.net was not met, but we saw a very provocative result in IgG/IgM responders…. Further development is clearly warranted.”

Read more at http://www.ascopost.com/issues/july-25-2016/quick-takes-on-promising-new-approaches-to-treating-breast-cancer/